Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18593134 | 0.69 | CYP11B1 (0.36) | KCNN4KCNA3CYP11B1CYP11B2 | |
| SCHEMBL2192084 | 0.68 | TDP2 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL2392374 | 0.67 | KCNN4 (0.69) | KCNN4KCNA3CA2CYP11B1CYP11B2 | |
| SCHEMBL3043828 | 0.67 | CA12 (0.61) | CA12CA1CA2CA9 | |
| SCHEMBL2190750 | 0.67 | TNKS (0.36) | KCNN4 | |
| SCHEMBL4240350 | 0.67 | MAP4K4 (0.40) | KCNN4KCNA3CYP11B1CYP11B2 | |
| SCHEMBL5800759 | 0.66 | KMT2A (0.52) | KCNN4KCNA3CYP11B1CYP11B2 | |
| SCHEMBL27172260 | 0.66 | EP300 (0.49) | CA12CA1CA2CA9AURKA | |
| SCHEMBL3852141 | 0.65 | KDM4E (0.47) | KCNN4KCNA3CYP11B1CYP11B2 | |
| SCHEMBL9404829 | 0.65 | DYRK1A (0.42) | KCNN4KCNA3CA2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | SB PHARMCO PUERTO RICO INC | 2011-07-14 | — | — | US | disclosed |
| EP-2186813-A1 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SmithKline Beecham (Cork) Limited (IE) | 2010-05-19 | — | — | EP | disclosed |
| CN-101434604-A | Condensed n-heterocyclic compounds and their use as CRF receptor antagonists | SB PHARMCO INC (IE) | 2009-05-20 | — | — | CN | disclosed |
| US-7427630-B2 | Condensed N-heterocyclic compounds and their use as CRF receptor antagonists | SB PHARMACO PUERTO RICO INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | NEUROCRINE BIOSCIENCES, INC. | 2007-01-04 | — | — | US | disclosed |
| CN-1805958-A | fused N-heterocyclic compounds and their use as CRF receptor antagonists | SB PHARMCO INC (PR) | 2006-07-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172255-A1 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists | CRH, CRHR1, CRHR2 | KCNN4 2829/4885KCNA3 2794/4885CA12 2330/4885 |
| US-20070004708-A1 | Condensed n-heterocyclic compounds and their use as crf receptor antagonists | CRHR2, NR3C2, CRHR1 | KCNN4 1112/4885KCNA3 891/4885CA12 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.